Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
An open-label, multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia
To document that RO0503821 administered for prolonged periods is efficacious, safe and well tolerated in patients treated for chronic renal anemia
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®
To determine reversibility of eGFRMDRD decrease following 52 weeks of 150 μg aleglitazar treatment and 8 weeks follow up observation after the last study medication, in patients with T2D and moderate ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC with Perjeta and Docetaxel in Patients with HER2-positive Advanced Breast Cancer
The primary objective for this study is to evaluate the safety and tolerability of Herceptin SC in combination with Perjeta IV plus docetaxel in patients with HER2−positive advanced (metastatic or loc...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Study Evaluating the Safety, Tolerability and Anti-tumor Activity of Polatuzumab Vedotin in Combination with Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
- Phase 1b: Safety and tolerability of the combination of polatuzumab vedotin with bendamustine and rituximab (BR) or bendamustine and obinutuzumab (BG) when administered to patients with relapsed or ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 6 ans
Etude WO29479 : étude randomisée de phase 2, en double aveugle, évaluant la sécurité et l’efficacité du cobimetinib en association avec du paclitaxel, de l’atézolizumab et du paclitaxel ou de l’atézolizumab et du nab-paclitaxel comme traitement de 1ère intention chez des patients ayant un cancer du sein métastatique triple négatif.
Le cancer du sein est le cancer le plus fréquent chez la femme. De nombreuses cellules du cancer du sein ont des récepteurs d’oestrogènes ou de progestérone, ou aussi des récepteurs pour une protéine ...
Country
France
organs
Sein
Specialty
Thérapies Ciblées
,
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
An open-label, non-controlled study of bevacizumab in combination with cisplatin-gembitabine or carboplatin-paclitaxel, as first line treatment for patients with advanced or recurrent squamous non-small cell lung cancer (NSCLC)
To assess the feasibility of using bevacizumab plus cisplatingemcitabine or carboplatin-paclitaxel in patients with squamous NSCLC considered to be at major risk for pulmonary haemorrhage*, when using...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients who are Chemotherapy-Naive and have Stage IV Non-Squamous Non-Small Cell Lung Cancer
•To evaluate the efficacy of atezolizumab (atezo) as measured by investigator-assessed progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1....
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
Hoffmann-La Roche MO19390 : Essai de phase 4 évaluant un traitement de 1ère ligne associant bévacizumab et une chimiothérapie à base de platine chez des patients ayant un cancer du poumon. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Open Label Study of Avastin in Combination With Platinum-Containing Chemotherapy as 1st Line Treatment in Patients With Stage IIIb/IV Non-Squamous NSCLC.
Country
France
organs
Appareil respiratoire - autres
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A randomized, double-blind, placebo controlled, parallel group study to investigate the effect of Taspoglutide on gastric emptying measured by a paracetamol test after single dose and after multiple doses in patients with Type 2 diabetes
To evaluate the effect of taspoglutide on gastric emptying (as assessed by the pharmacokinetics of paracetamol) after first and multiple dose of taspoglutide.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A study of the safety, efficacy, and tolerability of combination treatment of setrobuvir, danoprevir, ritonavir, and Copegus® with or without mericitabine in patients infected with the Hepatitis C virus who never received treatment before
• To evaluate the safety, tolerability and efficacy (SVR-12) of 12 or 24 weeks of treatment with an IFN-free regimen of STV, DNV/r, and RBV, with or without MCB, in treatment-naïve CHC genotype 1 pati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
17
18
19
20
21
22
23
24
25
26
Next